These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 12738677)

  • 41. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.
    Morel P; Hebbar M; Lai JL; Duhamel A; Preudhomme C; Wattel E; Bauters F; Fenaux P
    Leukemia; 1993 Sep; 7(9):1315-23. PubMed ID: 8371581
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate.
    Delgado J; Pratt G; Phillips N; Briones J; Fegan C; Nomdedeu J; Pepper C; Aventin A; Ayats R; Brunet S; Martino R; Valcarcel D; Milligan D; Sierra J
    Br J Haematol; 2009 Jun; 145(6):801-5. PubMed ID: 19388937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.
    Efficace F; Cottone F; Abel G; Niscola P; Gaidano G; Bonnetain F; Anota A; Caocci G; Cronin A; Fianchi L; Breccia M; Stauder R; Platzbecker U; Palumbo GA; Luppi M; Invernizzi R; Bergamaschi M; Borin L; Di Tucci AA; Zhang H; Sprangers M; Vignetti M; Mandelli F
    Cancer; 2018 Mar; 124(6):1251-1259. PubMed ID: 29231969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of epidemiological factors in survival of patients with de novo myelodysplastic syndromes.
    Kplola Y; Gbito E; Garcia-Manero G; Strom SS
    Cancer Causes Control; 2014 Apr; 25(4):425-35. PubMed ID: 24463789
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating myeloid colony-forming cells predict survival in myelodysplastic syndromes.
    Berer A; Jäger E; Sagaster V; Streubel B; Wimazal F; Sperr WR; Welterman A; Schwarzinger I; Frommlet F; Haas OA; Valent P; Lechner K; Geissler K; Ohler L
    Ann Hematol; 2003 May; 82(5):271-7. PubMed ID: 12739063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic significance of serial determinations of lactate dehydrogenase in follow-up for patients with myelodysplastic syndrome].
    Zhang YQ; Dai HB; Wang JH; Li XY; Dai SM; Yao DD; Ma LL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):85-9. PubMed ID: 21362228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic prognostic value of the revised international prognostic scoring system following pretransplant hypomethylating treatment in myelodysplastic syndrome.
    Yahng SA; Jeon YW; Yoon JH; Shin SH; Lee SE; Choi YS; Kim DY; Lee JH; Cho BS; Eom KS; Lee S; Min CK; Kim HJ; Lee JW; Lee KH; Min WS; Lee JH; Kim YJ
    Bone Marrow Transplant; 2017 Apr; 52(4):522-531. PubMed ID: 27892952
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).
    Yao CY; Hou HA; Lin TY; Lin CC; Chou WC; Tseng MH; Chiang YC; Liu MC; Liu CW; Kuo YY; Wu SJ; Liao XW; Lin CT; Ko BS; Chen CY; Hsu SC; Li CC; Huang SY; Yao M; Tang JL; Tsay W; Liu CY; Tien HF
    Oncotarget; 2016 Sep; 7(39):63177-63188. PubMed ID: 27527853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myelodysplastic Syndrome in Pakistan: Clinicohematological Characteristics, Cytogenetic Profile, and Risk Stratification.
    Mahmood R; Altaf C; Ahmed P; Khan SA; Malik HS
    Turk J Haematol; 2018 May; 35(2):109-115. PubMed ID: 28588002
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.
    Wang W; Routbort MJ; Tang Z; Ok CY; Patel KP; Daver N; Garcia-Manero G; Medeiros LJ; Wang SA
    Eur J Haematol; 2017 Dec; 99(6):536-543. PubMed ID: 28926144
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study.
    Efficace F; Gaidano G; Breccia M; Voso MT; Cottone F; Angelucci E; Caocci G; Stauder R; Selleslag D; Sprangers M; Platzbecker U; Ricco A; Sanpaolo G; Beyne-Rauzy O; Buccisano F; Palumbo GA; Bowen D; Nguyen K; Niscola P; Vignetti M; Mandelli F
    Lancet Oncol; 2015 Nov; 16(15):1506-1514. PubMed ID: 26404501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes.
    Pardanani A; Finke C; Lasho TL; Al-Kali A; Begna KH; Hanson CA; Tefferi A
    Leukemia; 2012 Apr; 26(4):693-9. PubMed ID: 21912394
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML).
    Hasle H; Baumann I; Bergsträsser E; Fenu S; Fischer A; Kardos G; Kerndrup G; Locatelli F; Rogge T; Schultz KR; Starý J; Trebo M; van den Heuvel-Eibrink MM; Harbott J; Nöllke P; Niemeyer CM;
    Leukemia; 2004 Dec; 18(12):2008-14. PubMed ID: 15496981
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome.
    Zuo Z; Calin GA; de Paula HM; Medeiros LJ; Fernandez MH; Shimizu M; Garcia-Manero G; Bueso-Ramos CE
    Blood; 2011 Jul; 118(2):413-5. PubMed ID: 21602527
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical features and prognosis of patients with myelodysplastic syndromes who were exposed to atomic bomb radiation in Nagasaki.
    Matsuo M; Iwanaga M; Kondo H; Soda M; Jo T; Horio K; Takasaki Y; Kawaguchi Y; Tsushima H; Imaizumi Y; Imanishi D; Taguchi J; Sawayama Y; Hata T; Miyazaki Y
    Cancer Sci; 2016 Oct; 107(10):1484-1491. PubMed ID: 27487572
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival analysis and AML development in patients with de novo myelodysplastic syndromes: comparison of six different prognostic scoring systems.
    Sperr WR; Wimazal F; Kundi M; Fonatsch C; Thalhammer-Scherrer R; Schernthaner GH; Schwarzinger I; Haas OA; Geissler K; Lechner K; Valent P
    Ann Hematol; 2001 May; 80(5):272-7. PubMed ID: 11446729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
    Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
    J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mesenchymal stromal cell density is increased in higher grade myelodysplastic syndromes and independently predicts survival.
    Johnson RC; Kurzer JH; Greenberg PL; Gratzinger D
    Am J Clin Pathol; 2014 Dec; 142(6):795-802. PubMed ID: 25389333
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients.
    Liabeuf S; Lenglet A; Desjardins L; Neirynck N; Glorieux G; Lemke HD; Vanholder R; Diouf M; Choukroun G; Massy ZA;
    Kidney Int; 2012 Dec; 82(12):1297-303. PubMed ID: 22895515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome.
    Valcárcel D; Ademà V; Solé F; Ortega M; Nomdedeu B; Sanz G; Luño E; Cañizo C; de la Serna J; Ardanaz M; Marco V; Collado R; Grau J; Montoro J; Mallo M; Vallespí T
    J Clin Oncol; 2013 Mar; 31(7):916-22. PubMed ID: 23319689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.